Academic Journal
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
| العنوان: | A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer |
|---|---|
| المؤلفون: | Takada, Masahiro, Imoto, Shigeru, Ishida, Takanori, Ito, Yoshinori, Iwata, Hiroji, Masuda, Norikazu, Mukai, Hirofumi, Saji, Shigehira, Ikeda, Takafumi, Haga, Hironori, Saeki, Toshiaki, Aogi, Kenjiro, Sugie, Tomoharu, Ueno, Takayuki, Ohno, Shinji, Ishiguro, Hiroshi, Kanbayashi, Chizuko, Miyamoto, Takeshi, Hagiwara, Yasuhiro, Toi, Masakazu |
| المساهمون: | Taiho Pharmaceutical |
| المصدر: | Breast Cancer Research and Treatment ; volume 202, issue 3, page 485-496 ; ISSN 0167-6806 1573-7217 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2023 |
| الوصف: | Purpose The Phase III POTENT trial demonstrated the efficacy of adding S-1 to adjuvant endocrine therapy for estrogen receptor-positive, HER2-negative early breast cancer. We investigated the efficacy of S-1 across different recurrence risk subgroups. Methods This was a post-hoc exploratory analysis of the POTENT trial. Patients in the endocrine-therapy-only arm were divided into three groups based on composite risk values calculated from multiple prognostic factors. The effects of S-1 were estimated using the Cox model in each risk group. The treatment effects of S-1 in patients meeting the eligibility criteria of the monarchE trial were also estimated. Results A total of 1,897 patients were divided into three groups: group 1 (≤ lower quartile of the composite values) ( N = 677), group 2 (interquartile range) ( N = 767), and group 3 (> upper quartile) ( N = 453). The addition of S-1 to endocrine therapy resulted in 49% (HR: 0.51, 95% CI: 0.33–0.78) and 29% (HR: 0.71, 95% CI 0.49–1.02) reductions in invasive disease-free survival (iDFS) events in groups 2 and 3, respectively. We could not identify any benefit from the addition of S-1 in group 1. The addition of S-1 showed an improvement in iDFS in patients with one to three positive nodes meeting the monarchE cohort 1 criteria ( N = 290) (HR: 0.47, 95% CI: 0.29–0.74). Conclusions The benefit of adding adjuvant S-1 was particularly marked in group 2. Further investigations are warranted to explore the optimal usage of adjuvant S-1. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1007/s10549-023-07099-4 |
| DOI: | 10.1007/s10549-023-07099-4.pdf |
| DOI: | 10.1007/s10549-023-07099-4/fulltext.html |
| الاتاحة: | http://dx.doi.org/10.1007/s10549-023-07099-4 https://link.springer.com/content/pdf/10.1007/s10549-023-07099-4.pdf https://link.springer.com/article/10.1007/s10549-023-07099-4/fulltext.html |
| Rights: | https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0 |
| رقم الانضمام: | edsbas.19097E5F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s10549-023-07099-4 |
|---|